Monday , 24 June 2024

Pharmacogenomic Study of Human Polycystic Kidney Disease

Author Details
V. Judia Harriet Sumathy*
Postgraduate and Research Department of Biotechnology, Women’s Christian College, Chennai–600006, TN, India

We are now entering an era of the mass-analysis of genetic information, which will signal the beginning of the study of living organisms on the basis of their most detailed plan: the DNA base-sequences. Throughout the 20th century, the chief epidemiologic impression of polycystic kidney disease (PKD) has been what an early observer described as its outstandingly hereditary character. An Autosomal dominant form of the disease is indeed among the most common genetic disorders, with an incidence of roughly one person in every thousand. Overall, the disease accounts for as much as 5% of all cases of chronic renal failure.. The researcher’s essential requirement in reading and deciphering the DNA base-sequence is the precision, speed, reliability, and low cost of such operation.  In the early days of genetics, scientists did not have the resources to look at more than a few genes at a time. This made the process of understanding the influence of genetics on an organism slow and arduous.  Scientists were faced with the enormous task of attempting to understand Genetics with little information to complete the task.  The understanding of genes would have been very helpful in solving this problem. With the announcement in June of 2001 that the first draft of the human genome had been completed, scientists’ approach to biology completely changed. This is a first attempt study in Indian scenario initiated to conduct a Pharmacogenomic study of Human Polycystic Kidney Disease.
Keywords: Polycystic kidney disease, Genetic information, DNA base-sequence, Human genome and Pharmacogenomic study


Scroll To Top